Skip to main content
. 2020 Aug 20;20:402. doi: 10.1186/s12935-020-01491-6

Table 2.

Univariate and multivariate Cox regression analysis of clinical-factors/risk-score with overall survival rate in patients

Variables Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
TCGA-BLCA
 Age 1.04 (1.02–1.06) 1.20E05 1.02 (0.99–1.05) 2.69E−01
 Gender 1.11 (0.78-1.58) 5.56E−01 1.44 (0.81–2.54) 2.14E−01
 Grade 9,608,547.45 (0-Inf) 9.91E−01 5,878,954.98 (0-Inf) 9.96E−01
 Stage 1.81 (1.47-2.23) 2.62E08 0.89 (0.42–1.88) 7.63E−01
 T stage 1.75 (1.37-2.24) 6.57E06 1.38 (0.82–2.34) 2.23E−01
 Node 1.61 (1.35-1.91) 8.06E08 1.44(0.86-2.41) 1.64E−01
 Metastasis 3.06 (1.39-6.73) 5.44E03 0.88(0.28-2.72) 8.24E−01
 Risk score 3.75 (2.43-5.79) 2.46E09 4.1(1.89-8.91) 3.67E04
GSE13507
 Age 1.07 (1.04–1.1) 4.53E08 1.07 (1.04–1.1) 8.71E06
 Gender 1.56 (0.88–2.77) 1.29E−01 1.57 (0.81–3.03) 1.81E−01
 Grade 1.9 (1.49–2.42) 2.46E07 1 (0.54–1.86) 9.97E−01
 Stage 2.74 (1.69–4.43) 4.00E05 1.06 (0.52–2.14) 8.70E−01
 T stage 2.05 (1.64–2.58) 5.06E10 1.51 (0.82–2.79) 1.83E−01
 Node 3.32 (2.23–4.94) 3.88E09 2.21 (1.09–4.46) 2.71E02
 Metastasis 9.9 (4.38–22.37) 3.64E08 3.61 (1.2–10.86) 2.21E02
 Risk score 11.16 (4.22–29.47) 1.14E06 1.33 (0.26–6.87) 7.37E−01
GSE32548
 Age 1.04 (0.99–1.08) 9.34E−02 1.06 (1.01–1.1) 2.00E02
 Gender 0.78 (0.29–2.07) 6.13E−01 0.66 (0.23–1.85) 4.27E−01
 Grade 2.26 (1.07–4.77) 3.26E02 0.46 (0.15–1.44) 1.83E−01
 T stage 3.53 (1.89–6.6) 7.42E05 3.97 (1.58–9.99) 3.41E03
 Risk score 43.5 (6.85–276.49) 6.37E05 12.81 (1.06–154.42) 4.46E02
GSE32894
 Age 0.98 (0.95–1.01) 1.79E−01 0.97 (0.92–1.01) 1.63E−01
 Gender 1.47 (0.55–3.93) 4.45E−01 1.35 (0.49–3.74) 5.61E−01
 Grade 7.59 (2.45–23.52) 4.45E04 3.58 (1.05–12.13) 4.08E02
 T stage 0.98 (0.62–1.56) 9.42E−01 1 (0.58–1.7) 9.86E−01
 Risk score 140.69 (25.35–780.79) 1.54E08 31.03 (3.79–253.97) 1.36E03

Italic font means statistically significant

HR hazard ratio, CI confidence interval, Inf infinity